Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."

TSX:MSL - Post Discussion

MERUS LABS INTERNATIONAL INC > Earnings out...
View:
Post by felix10 on Aug 10, 2015 7:43pm

Earnings out...

https://www.newswire.ca/news-releases/merus-labs-reports-q3-2015-results-521323841.html][/url]
Comment by felix10 on Aug 10, 2015 7:47pm
Sorry, in the previous post, the link should end with .html
Comment by boomchickawawa on Aug 10, 2015 8:02pm
Wow nice jump up in revenues! Next quarter should show a real nice profit when the u.s. dollar keeps coming down, especially when everyone realizes that america cannot raise intrerest rates ever!!!!!!!!!!!!!!!
Comment by lscfa on Aug 10, 2015 8:15pm
Since results fluctuated with timing of inventory MSL should have emphasized growth rates for longer periods. e.g. Q3 yoy rev growth 32% 6 month yoy rev growth 61% 9 month yoy rev growth 63%
Comment by lscfa on Aug 11, 2015 9:31am
Accounting distortions are misleading. Net rev growth for the qtr was 32% but gross rev growth was 90%. Also cash flow from operations was 81%......  
Comment by lscfa on Aug 10, 2015 8:26pm
Guidance suggests Q4 should be big..... "While we had a challenging third quarter, adjusted EBITDA, without factoring in new acquisitions, is expected to be in the low-mid $30M range for both fiscal 2015 and 2016," commented Mr. Fishman. Q1 $7.6 million Q2 $9.4 million Q3 $6.4 million Q4 will be $32 - 23.4 = $8.6 million to $35 - 23.4 = $11.6 million
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities